There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition.
In an upcoming webinar, which will be hosted on May 26, two expert speakers will be discussing how researchers can enhance the predictability of pre-clinical drug development.
This webinar, Enhancing the predictability of preclinical development, hosted by DDW and supported by PerkinElmer, will take place on 26 May at 4PM BST; 8AM PDT; 11 AM EDT; 5PM CEST.
Dr. Seyoum Ayehunie, Vice President, Scientific Research and Development, MatTek Corporation, will discuss the functionality and limitations of a novel in vitro 3D primary human cell-based tissue model for drug toxicity and efficacy studies.
This talk will be followed by a presentation from Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals, (pictured), who will explain why developing a predictive pre-clinical assay is key to success in immuno-oncology drug development.
Key Learning Objectives:
- How to evaluate models to establish robust and reliable preclinical investigation of drug candidates prior to entering clinical trials
- How to gain an understanding of the advancements in preclinical model systems and assays
- What to consider from the latest innovations and impact on bioanalytical assays
Who Should Attend:
- Preclinical development scientists
- Bioanalytical assay development scientists
- Analytical scientists